MEDICINOVA INC. - COMMON STOCK

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

05 Dec 2024 17:00:00 By Nasdaq GlobeNewswire

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

19 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

14 Nov 2024 17:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: MEDICINOVA INC. - COMMON STOCK

12 Nov 2024 12:48:52 By NetDania Notify

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

11 Nov 2024 17:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

23 Oct 2024 18:00:00 By Nasdaq GlobeNewswire

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

30 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

09 Sep 2024 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

03 Sep 2024 18:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

29 Aug 2024 18:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: MEDICINOVA INC. - COMMON STOCK

12 Aug 2024 10:21:20 By NetDania Notify

NetDania - New 12 months Low: MEDICINOVA INC. - COMMON STOCK

07 Aug 2024 14:10:41 By NetDania Notify

NetDania - New 12 months Low: MEDICINOVA INC. - COMMON STOCK

06 Aug 2024 09:25:17 By NetDania Notify

NetDania - New 12 months Low: MEDICINOVA INC. - COMMON STOCK

05 Aug 2024 08:46:33 By NetDania Notify

MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations

20 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

05 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

03 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

28 May 2024 05:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

20 May 2024 05:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

14 May 2024 05:00:00 By Nasdaq GlobeNewswire